COMMD8 changes expression during initial phase of wasp venom immunotherapy
© 2020 John Wiley & Sons, Ltd..
BACKGROUND: Hymenoptera venom allergy (HVA) is of great concern because of the possibility of anaphylaxis, which may be fatal. Venom immunotherapy (VIT) is the only disease-modifying treatment in HVA and, although efficient, its mechanism remains partially unknown. Gene expression analysis may be helpful for establishing a proper model of tolerance induction during the build-up phase of VIT. The present study aimed to analyze how the start of VIT changes the expression of 15 selected genes.
METHODS: Forty-five patients starting VIT with a wasp venom allergy were enrolled. The diagnosis was established based on anaphylaxis history (third or fourth grade on the Mueller scale) and positive soluble immunoglobulin E and/or skin tests. Two blood collections were performed in the patient group: before and after 3 months of VIT. One sample was taken in the control group. Gene expression analysis was performed using a reverse transcriptase-polymerase chain reaction with microfluidic cards and normalized to the 18S housekeeping gene.
RESULTS: Commd8 was the only gene that changed expression significantly after the start of VIT (p = 0.012). Its expression decreased towards the levels observed in the healthy controls. Twelve out of 15 genes (commd8, cldn1, cngb3, fads1, hes6, hla-drb5, htr3b, prlr, slc16a4, snx33, socs3 and twist2) revealed a significantly different expression compared to the healthy controls.
CONCLUSIONS: The present study shows that commd8 changes significantly its expression during initial phase of VIT. This gene might be a candidate for VIT biomarker in future studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
The journal of gene medicine - 22(2020), 11 vom: 01. Nov., Seite e3243 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kempiński, Karol [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jgm.3243 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311376800 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311376800 | ||
| 003 | DE-627 | ||
| 005 | 20231225142124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jgm.3243 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311376800 | ||
| 035 | |a (NLM)32559011 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kempiński, Karol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMMD8 changes expression during initial phase of wasp venom immunotherapy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons, Ltd. | ||
| 520 | |a BACKGROUND: Hymenoptera venom allergy (HVA) is of great concern because of the possibility of anaphylaxis, which may be fatal. Venom immunotherapy (VIT) is the only disease-modifying treatment in HVA and, although efficient, its mechanism remains partially unknown. Gene expression analysis may be helpful for establishing a proper model of tolerance induction during the build-up phase of VIT. The present study aimed to analyze how the start of VIT changes the expression of 15 selected genes | ||
| 520 | |a METHODS: Forty-five patients starting VIT with a wasp venom allergy were enrolled. The diagnosis was established based on anaphylaxis history (third or fourth grade on the Mueller scale) and positive soluble immunoglobulin E and/or skin tests. Two blood collections were performed in the patient group: before and after 3 months of VIT. One sample was taken in the control group. Gene expression analysis was performed using a reverse transcriptase-polymerase chain reaction with microfluidic cards and normalized to the 18S housekeeping gene | ||
| 520 | |a RESULTS: Commd8 was the only gene that changed expression significantly after the start of VIT (p = 0.012). Its expression decreased towards the levels observed in the healthy controls. Twelve out of 15 genes (commd8, cldn1, cngb3, fads1, hes6, hla-drb5, htr3b, prlr, slc16a4, snx33, socs3 and twist2) revealed a significantly different expression compared to the healthy controls | ||
| 520 | |a CONCLUSIONS: The present study shows that commd8 changes significantly its expression during initial phase of VIT. This gene might be a candidate for VIT biomarker in future studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a RNA | |
| 650 | 4 | |a allergy | |
| 650 | 4 | |a gene expression | |
| 650 | 4 | |a immune response | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Delta-5 Fatty Acid Desaturase |2 NLM | |
| 650 | 7 | |a Wasp Venoms |2 NLM | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 650 | 7 | |a FADS1 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.19.3 |2 NLM | |
| 700 | 1 | |a Romantowski, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Maciejewska, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Pawłowski, Ryszard |e verfasserin |4 aut | |
| 700 | 1 | |a Chełmińska, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Jassem, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Niedoszytko, Marek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of gene medicine |d 1997 |g 22(2020), 11 vom: 01. Nov., Seite e3243 |w (DE-627)NLM09753630X |x 1521-2254 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:11 |g day:01 |g month:11 |g pages:e3243 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jgm.3243 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 11 |b 01 |c 11 |h e3243 | ||